Sangamo Biosciences, Inc. (NASDAQ:SGMO), a leader in therapeutic genome editing, announced today the publication in Nature Biotechnology of data demonstrating efficient zinc finger …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), a leader in therapeutic genome editing, announced today that non-human primate data from its proprietary In Vivo Protein Replacement …
Sangamo Biosciences, Inc. (NASDAQ:SGMO) reported its third quarter 2015 financial results and accomplishments.
Sangamo Biosciences, Inc. (NASDAQ:SGMO) presented data demonstrating sustained functional control of viral load in the absence of antiretroviral drugs (ART) in two of …
Sangamo Biosciences, Inc. (NASDAQ:SGMO), a leader in therapeutic genome editing, announced unanimous approval by the National Institutes of Health’s Recombinant DNA Advisory Committee …
In a research report released Friday, Cowen’s healthcare analyst Ritu Baral shed some light on Sangamo Biosciences, Inc. (NASDAQ:SGMO), after the company announced a restructuring of …
Yesterday, Sangamo Biosciences, Inc. (NASDAQ:SGMO) announced it will be restructuring its collaboration with Shire PLC (ADR) (NASDAQ:SHPG) in order to speed up the …
In a research report published Wednesday, J.P.
Wedbush analyst Liana Moussatos weighed in today with a few insights on Sangamo Biosciences, Inc. (NASDAQ:SGMO), after the company announced that it has regained the rights …
Sangamo BioSciences, Inc. (NASDAQ:SGMO), a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire PLC (ADR) (NASDAQ:SHPG), have agreed …
